115kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity

Immunobiology

Volumn 218, Issue 1, 2013, Pages 114-126

  Choudhury, Rajdeep ^a,c   Das, Partha ^a   De, Tripti ^b   Chakraborti, Tapati ^a  

^a UNIVERSITY OF KALYANI   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Extracellular serine protease; Immunization; Leishmania donovani; Matrix metalloprotease 9; Visceral leishmaniasis

Indexed keywords

GAMMA INTERFERON; GELATINASE B; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MESSENGER RNA; SERINE PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; IMMUNOLOGICAL ADJUVANT; LEISHMANIA VACCINE; PROTOZOAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFLAMMATION; LEISHMANIA DONOVANI; LIVER; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SPLEEN; T LYMPHOCYTE; VACCINATION; VISCERAL LEISHMANIASIS; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; SERINE PROTEASES; TH1 CELLS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870291040     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.02.008     Document Type: Article

References (70)

1. Afrin F., Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect. Immun. 1997, 65:2371-2377.
2. Alves C.F., de Amorim I.F.G., Moura E.P., Ribeiro R.R., Michalick M.S.O., Kalapothakis E., Bruna R., Tafuri W.L., Teixeira M.M., Melo M.N. Experession of IFN-gama TNF-(and TGF-β in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with Leishmania chagasi. Vet. Immunol. Immunopathol. 2009, 128:349-358.
3. Ashman R.B., Vijayan D., Wells C.A. IL-12 and related cytokines: function and regulatory implications in Candida albicans infection. Clin. Dev. immunol. 2010, 2011:1-9.
4. Bates P.A. Transmission of Leishmania metacyclic promastigotes by phlebotoine sand flies. Int. J. Parasitol. 2007, 37:1097-1106.
5. Bhaumik S., Basu R., Sen S., Naskar K., Roy S. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for complete protection against L. major. Vaccine 2009, 27:1306-1316.
6. Bhowmick S., Mazumdar T., Ali N. Vaccination route that induces transforming growth factor β production fails to elicit protective immunity against Leishmania donovani infection. Infect. Immun. 2009, 77:1514-1523.
7. Bhowmick S., Ravindran R., Ali N. Gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect. Immun. 2008, 76:1003-1015.
8. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-g. Annu. Rev. Immunol. 1997, 15:749-795.
9. Carrillo E., Crusat M., Nieto J., Chicharro C., Thomas Mdel C., Martínez E., Valladares B., Cañavate C., Requena J.M., López M.C., Alvar J., Moreno J. Immunogenicity of HSP-70 KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine 2008, 26:1902-1911.
10. Carvalho D.G., Barbosa, D'EL-Rei H.M., Clarencio J., PinheiroJr N.F., Veras P.S., dos-Santos W.L. The modeling of mononuclear phagocytes-connective tissue adhesion in vitro; application to disclose a specific inhibitory effect of Leishmania infection. Exp. parasitol. 2004, 107:189-199.
11. Choudhury R., Bhaumik S.K., De T., Chakraborti T. Identification, purification and characterization of a secretory serine protease in an Indian strain of Leishmania donovani. Mol. Cell. Biochem. 2009, 320:1-14.
12. Choudhury R., Das P., Bhaumik S.K., De T., Chakrabort T. In situ immunolocalizaton and stage-dependent expression of a secretory serine protease in Leishmania donovani and its role as a vaccine candidate. Clin. Vaccine Immunol. 2010, 17:660-667.
13. Coffman R.L., Lebman D.A., Rothman P. Mechanism and regulation of immunoglobin isotype switching. Adv. Immunol. 1993, 54:229-270.
14. Coler R.N., Reed S.G. Second generation vaccines against leishmaniasis. Trends Parasitol. 2005, 21:244-249.
15. Costa J.D., Nogueira de Melo A.C., Vermelho A.B., Meirelles Mde N., Porrozzi R. In vitro evidence for metallopeptidase participation in hepatocyte damage induced by Leishmania chagasi-infected macrophages. Acta Trop. 2008, 106:175-183.
16. Croft S.L. Recent development in the chemotherapy of leishmaniasis. Trends Pharmacol. Sci. 1988, 9:376-381.
17. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 2004, 27:305-318.
18. Dole V.S., Raj V.S., Ghosh A., Madhubala R., Myler P.J., Stuart K.D. Immunization with recombinant LD1 antigen protects against visceral leishmaniasis. Vaccine 2000, 19:423-430.
19. Elkington P.T., Emerson J.E., Lopez-Pascua L.D., O'Kane C.M., Horncastle D.E., Boyle J.J., Friedland J.S. Mycobacterium tuberculosis up-regulates matrix metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch. J. Immunol. 2005, 175:5333-5340.
20. Furundzija V., Fritzsche J., Kauffmann J., Meyborg H., Fleck E., Kaput K., Stawowy P. IGF-1 increases macrophage motility via PKc/p38 dependent alpha-beta 3-integrin inside-out signaling. Biochem. Biophys. Res. Commun. 2010, 394:786-791.
21. Geurts N., Opendenakker G., Vanden steen P.E. Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol. Ther. 2012, 133:257-279.
22. Handman E., Symons F.M., Baldwin T.M., Curtis J.M., Scheerlinck J.P.Y. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a Th1 type of immune response. Infect. Immun. 1995, 63:4261-4267.
23. Heinzel F.P., Sadick M.D., Mutha S.S., Locksley R.M. Production of interferon gamma, interleukin 2, interleukin-4 and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. 1991, 88:7011-7015.
24. Held T.K., Welhua X., Yuan L., Kalvakolanu D.V., Crass A.S. Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1. Infect. Immun. 1999, 67:206-212.
25. Howard J.C. Immunological regulation and control of experimental leishmaniasis. Int. Rev. Exp. Pathol. 1986, 28:79-116.
26. Jaafari M.R., Ghafarian A., Farrokh-Gisour A., Samiei A., Kheiri M.T., Mahboudi F., Barkhordari F., Khamesipour A., McMaster W.R. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 2006, 24:5708-5717.
27. Kawano Y., Noma T., Yata J. Regulation of human IgG subclass production by cytokines. IFNγ and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2. J. Immunol. 1994, 153(11):4948-4958.
28. Kemp M., Handman E., Kemp K. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognized by Th1 cells in humans with naturally acquired immunity to L. major. Immunol. Med. Microbiol. 1999, 3:209-218.
29. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 1970, 227:680-685.
30. Liew F.Y. Functional heterogeneity of CD4+ T cells in leishmaniasis. Immunol. Today 1989, 10:40-45.
31. Mauel J., Behin R. Immunity clinical and experimental. The Leishmaniasis in Biology and Medicine 2007, vol. 2:31-739. Academic Press, London.
32. McMahon-Pratt D., Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniasis or the visceral disease?. Immunol. Rev. 2004, 201:206-224.
33. McMahon Pratt D., Rodriguez D., Rodriguez J.R., Zhang Y., Manson K., Bergman C. Recombinant vaccinia viruses expessing GP-45/M2 protect against Leishmania infection. Infect. Immun. 1993, 61:3351-3359.
34. Melby P.C., Yang J., Zhao W., Perez L.E., Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 2001, 69:4719-4725.
35. Mendez S., Gurunathan S., Kamhawi S., Belkaid Y., Moga M.A., Skeiky Y.A., Campos-Neto A., Reed S., Seder R.A., Sacks D. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 2001, 166:5122-5128.
36. Mertz P.M., DeWitt D.L., Steler-Stevenson W.G., Wahl L.M. Interleukin-10 suppression of monocyte prostaglandin H synthase: mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J. Biol. Chem. 1994, 269:21322-21329.
37. Michael M.Y., Fathy F.M., Hegazy E.H., Hussein E.D., Eissa M.M., Said D.E. The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis. J. Egypt. Soc. Parasitol. 2006, 36:159-176.
38. Miralles G.D., Stoeckle M.Y., Mc Dermott D.F., Finkelman F.D., Murray H.W. Th-1 and Th-2 cell associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 1994, 62:1058.
39. Modabber F. First generation leishmaniasis vaccines in clinical development: moving but what next?. Curr. Opin. Anti-Infect. Investig. Drugs 2000, 2:35-39.
40. Mottram J.C., Coombs G.H., Alexander J. Cysteine peptidases as virulence factors of Leishmani. Curr. Opin. Microbiol. 2004, 7:375-381.
41. Munn E.A., Smith T.S., Smith H., James F.M., Smith F.C., Andrews S.J. Vaccination against Haemonchus contortus with denatured forms of the protective antigen H11. Parasite Immunol. 1997, 19:243-248.
42. Murray H.W., Berman J.D., Davies C.R., Saravia N.G. Advances in leishmaniasis. Lancet 2005, 366:1561-1577.
43. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol. Chem. 1997, 378:151-160.
44. Osenkrands I., Weldingh K., Ravn P., Brandt L., Højrup P., Rasmussen P.B., Coates A.R., Singh M., Mascagni P., Andersen P. Differential T-cell recognition of native and recombinant Mycobacterium tuberculosis GroES. Infect. Immun. 1999, 67:5552-5558.
45. Parody N., Soto M., Requena J.M., Alonso C. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG+Q mix protects Balb/c mice from infection. Parasite Immunol. 2004, 26:283-293.
46. Pearson M.S., Bethony J.M., Pickering D.A., de Oliveira L.M., Jariwala A., Santiago H., Miles A.P., Zhan B., Jiang D., Ranjit N., Mulvenna J., Tribolet L., Plieskatt J., Smith T., Bottazzi M.E., Jones K., Keegan B., Hotez P.J., Loukas A. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. FASEB J. 2009, 23:3007-3019.
47. Pinto E.F., Pinheiro R.O., Rayol A., Larraga V., Rossi-Bergmann B. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK. Infect. Immun. 2004, 72:4521-4527.
48. Pollock K.G., McNeil K.S., Mottram J.C., Lyons R.E., Brewer J.M., Scott P., Coombs G.H., Alexander J. The Leishmania mexicana cysteine protease CPB2. 8, induces potent Th2 responses. J. Immunol. 2003, 170:1746-1753.
49. Prato M., Giribaldi G., Polimeni M., Gallo V., Arese P. Phagocytosis of hemozoin enhances matrix metalloproteinase-9 activity and TNF-alpha production in human monocytes: role of matrix metalloproteinases in the pathogenesis of falciparum malaria. J. Immunol. 2005, 175:6436-6442.
50. Probst P., Skeiky Y.A., Steeves M., Gervassi A., Grabstein K.H., Reed S.G. A leishmanial protein that modulates interleukin 12 (IL-12), IL-10 and tumor necrosis factor alpha (TNF-α) production and expression of B 7-1 in human monocyte derived antigen presenting cells. Eur. J. Immunol. 1997, 27:2634-2642.
51. Rachamim N., Jaffe C.L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 1993, 150:2322-2331.
52. Redmond D.L., Knox D.P. Protection studies in sheep using affinity-purified and recombinant cysteine proteinases of adult Haemonchus contortus. Vaccine 2004, 22:4252-4261.
53. Roy S., Scherer M.T., Briner T.J., Smith J.A., Gefter M.L. Murine MHC polymorphism and T cell specificities. Science 1989, 244:572-575.
54. Sajid M., Mc Kerrow J.H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 2002, 120:1-21.
55. Saren P., Welgus H., Kovanen P. TNF-alfa and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol. 1996, 157:4159-4165.
56. Scott P., Trinchieri G. IL-12 as an adjuvant for cell mediated immunity. Semin. Immunol. 1997, 9:285-291.
57. Sheen P., O'kane C.M., Choudhury K., Tover M., Santillan C., Sosa J., Caviedes L., Gilman R.H., Stamp G., Friedland J.S. High MMP-9 activity characterizes pleural tuberculosis correlating with granuloma formation. Eur. Respir. J. 2009, 33:134-141.
58. Silva-Lopez Re., Coelho M.G., De Simone S.G. Characterization of an extracellular serine protease of Leishmania (Leishmania) amazonensis. Parasitology 2005, 131:85-96.
59. Stager S., Smith D.F., Kaye P.M. Immunization with recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 2000, 165:7064-7071.
60. Stanley A.C., Engweda C.R. Balancing immunity and pathology in visceral leishmaniasis. Immunol. Cell Biol. 2007, 85:138-147.
61. Sundar S., More D.K., Singh M.K., Singh V.P., Sharma S., Makharia A. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 2000, 31:1104-1107.
62. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 2001, 6:849-854.
63. Taylor J.L., Hattle J.M., Dreitz S.A., Troudt J.M., Izzo L.S., Basaraba R.J., Orme I.M., Matrisian L.M., Izz A.A. Role for matrix metalloproteinase-9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect. Immun. 2006, 74:6135-6144.
64. Teles R.M., Antunes S.L., Jardim M., Oliveira Rm., Nery A.L., Sales J.A., Sampaio A.M., Shubayev E.P., Sarno V.E.N. Expression of metalloproteinases (MMP-2 MMP-9, and TACE) and TNF-alpha in the nerves of leprosy patients. J. Peripher. Nerv. Syst. 2007, 12:195-204.
65. Teles R.M., Teles R.B., Amadeu T.P., Moura D.F., Mendonça-Lima L., Ferreira H., Santos I.M., Nery J.A., Sarno E.N., Sampaio E.P. High matrix metalloproteinase production correlates with immune activation and leukocyte migration in leprosy reactional lesions. Infect. Immun. 2010, 78:1012-1021.
66. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. 1979, 76:4350-4354.
67. Wang Z.E., Reiner S.L., Zheng S., Dalton D.K., Locksley R.M. CD4+ effector cells default to the Th2 pathway in interferon γ-deficient mice infected with L. major. J. Exp. Med. 1994, 179:1367-1371.
68. Wahl L.M., Corcoran M.E., Mergenhagen S.E., Finbloom D.S. Inhibition of phospholipase activity in human monocytes by IFN-γ blocks endogenous prostaglandin E2-dependent collagenase production. J. Immunol. 1990, 144:3518-3522.
69. Wilson M.E., Jeronimo S.M.B., Pearson R.D. Immunopathogenesis of infection with the visceralizing leishmania species. Microb. Pathog. 2005, 38:147-160.
70. Zhang Y., Mccluskey K., Fujii K., Wahl L.M. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-α, granulocyte-macrophage CSF, and IL-1β through prostaglandin-dependent and mechanisms. J. Immunol. 1998, 161:3071-3076.